Thresholds for clinically important deterioration versus improvement in COPD health status: Results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice

BMJ Open

Volumn 9, Issue 6, 2019, Pages

  Alma, Harma Johanna ^a   De Jong, Corina ^a   Jelusic, Danijel ^b   Wittmann, Michael ^b   Schuler, Michael ^c   Sanderman, Robbert ^a,d   Schultz, Konrad ^b   Kocks, Janwillem ^a   Van Der Molen, Thys ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Klinik Bad Reichenhall   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

chronic obstructive pulmonary disease; health status responsiveness; health related quality of life; minimal clinically important difference; pulmonary rehabilitation; routine clinical practice

Indexed keywords

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL COPD QUESTIONNAIRE; CLINICAL PRACTICE; CONTROLLED STUDY; COPD ASSESSMENT TEST; DETERIORATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; MIDDLE AGED; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; TIME FACTOR;

AGED; CLINICAL DETERIORATION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 85068859531     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2018-025776     Document Type: Article

References (45)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. 2017 http://www. goldcopd. org/ gold- 2017- global- strategy- diagnosismanagement- prevention- copd/ (Accessed 17 Jul 2017).
2. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-54.
3. van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003;1:13.
4. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Supplement B):25-31.
5. Cave AJ, Atkinson L, Tsiligianni IG, et al. Assessment of COPD wellness tools for use in primary care: an IPCRG initiative. Int J Chron Obstruct Pulmon Dis 2012;7:447-56.
6. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
7. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015;5:020415.
8. Kocks JW, Tuinenga MG, Uil SM, et al. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006;7:62.
9. Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax 2014;69:793-8.
10. Canavan JL, Dilaver D, Clark AL, et al. Clinical COPD Questionnaire in patients with chronic respiratory disease. Respirology 2014;19:1006-12.
11. Tsiligianni IG, van der Molen T, Moraitaki D, et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 2012;12:20.
12. Alma H, de Jong C, Jelusic D, et al. Health status instruments for patients with COPD in pulmonary rehabilitation: defining a minimal clinically important difference. NPJ Prim Care Respir Med 2016;26:16041.
13. Smid DE, Franssen FM, Houben-Wilke S, et al. Responsiveness and MCID Estimates for CAT, CCQ, and HADS in Patients With COPD Undergoing Pulmonary Rehabilitation: A Prospective Analysis. J Am Med Dir Assoc 2017;18:53-8.
14. Kon SS, Canavan JL, Jones SE, Nolan CM, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014;2:195-203.
15. Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011;66:425-9.
16. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2:75-9.
17. Welling JB, Hartman JE, Ten Hacken NH, et al. The minimal important difference for the St George's Respiratory Questionnaire in patients with severe COPD. Eur Respir J 2015;46:1598-604.
18. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-9.
19. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
20. Alma H, de Jong C, Tsiligianni I, et al. Clinically relevant differences in COPD health status: systematic review and triangulation. Eur Respir J 2018;52:1800412.
21. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395-407.
22. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9.
23. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 2002;14:109-14.
24. Hays RD, Woolley JM. The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it? Pharmacoeconomics 2000;18:419-23.
25. Raman S, Ding K, Chow E, et al. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy. Qual Life Res 2016;25:2535-41.
26. Maringwa J, Quinten C, King M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011;22:2107-12.
27. Hui D, Shamieh O, Paiva CE, et al. Minimal Clinically Important Difference in the Physical, Emotional, and Total Symptom Distress Scores of the Edmonton Symptom Assessment System. J Pain Symptom Manage 2016;51:262-9.
28. Tuomi L, Johansson M, Andrell P, et al. Interpretation of the Swedish Self Evaluation of Communication Experiences after Laryngeal cancer: Cutoff levels and minimum clinically important differences. Head Neck 2016;38:689-95.
29. Rouquette A, Blanchin M, Sebille V, et al. The minimal clinically important difference determined using item response theory models: an attempt to solve the issue of the association with baseline score. J Clin Epidemiol 2014;67:433-40.
30. Hui D, Shamieh O, Paiva CE, et al. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study. Cancer 2015;121:3027-35.
31. Singh D, D'Urzo AD, Chuecos F, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/ formoterol. Respir Res 2017;18:106.
32. Stockley RA, Edgar RG, Starkey S, et al. Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respir Res 2018;19:137.
33. Anzueto AR, Kostikas K, Mezzi K, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res 2018;19:121.
34. Naya IP, Tombs L, Muellerova H, et al. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res 2018;19:222.
35. Schultz K, Jelusic D, Wittmann M, et al. Inspiratory muscle training does not improve clinical outcomes in 3-week COPD rehabilitation: results from a randomised controlled trial. Eur Respir J 2018;51:1702000.
36. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther 2009;17:163-70.
37. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7.
38. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
39. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
40. de Vet HC, Terwee CB, Ostelo RW, et al. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes 2006;4:54.
41. Pothirat C, Chaiwong W, Limsukon A, et al. Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score. Int J Chron Obstruct Pulmon Dis 2015;10:277-82.
42. Garcia-Sidro P, Naval E, Martinez Rivera C, et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Respir Med 2015;109:1546-52.
43. Janse AJ, Gemke RJ, Uiterwaal CS, et al. Quality of life: patients and doctors don't always agree: a meta-analysis. J Clin Epidemiol 2004;57:653-61.
44. Yoo JY, Kim YS, Kim SS, et al. Factors affecting the trajectory of health-related quality of life in COPD patients. Int J Tuberc Lung Dis 2016;20:738-46.
45. Sundh J, Montgomery S, Hasselgren M, et al. Change in health status in COPD: a seven-year follow-up cohort study. NPJ Prim Care Respir Med 2016;26:16073.